Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Prostatype Genomics AB's Revenue for the
six
months ended in Dec. 2025 was kr0.35 Mil. Prostatype Genomics AB's average Accounts Receivable for the
six
months ended in Dec. 2025 was kr0.12 Mil.
Hence, Prostatype Genomics AB's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.97.
Prostatype Genomics AB (OSTO:PROGEN) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Prostatype Genomics AB Receivables Turnover Related Terms
Prostatype Genomics AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a Receivables Turnover of 2.97 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #59 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 29.2%.
Is Prostatype Genomics AB's Receivables Turnover too high?
Prostatype Genomics AB's current Receivables Turnover is 2.97. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Prostatype Genomics AB's value of 2.97 is 44.8% below this industry median. Based on the distribution chart, Prostatype Genomics AB ranks #59 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #59 out of 202 companies for Receivables Turnover. This puts Prostatype Genomics AB in the upper half of its industry. The industry median Receivables Turnover is 5.38. Prostatype Genomics AB's value of 2.97 is 44.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostatype Genomics AB's current Receivables Turnover of 2.97 is 44.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current Receivables Turnover is 2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.18 — trading 357.5% above its estimated fair value. The current Receivables Turnover is 2.97 and 44.8% below the Medical Diagnostics & Research industry median of 5.38. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Receivables Turnover is 2.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.18 is trading 357.5% above its estimated GF Value™ of kr0.04.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Receivables Turnover: 2.97
GF Value™: kr0.04 vs. price of kr0.18 (357.5% above fair value)
Industry Position: 44.8% below the Medical Diagnostics & Research median (#59 of 202)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for OSTO:PROGEN
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
